Mark T. Fleming, MD, Talks Use of 18F-rhPSMA-7.3 for PET/CT in Recurrent Prostate Cancer

Mark T. Fleming, MD, spoke about how use of 18F-rhPSMA-7.3 for PET/CT scans in patients with recurrent prostate cancer bests conventional imaging.

At the American Urological Association 2022 Annual Meeting, CancerNetwork® spoke with Mark T. Fleming, MD, medical director for the US Oncology Genitourinary Research Committee, Division Chief of Eastern Virginia Medical School Department of Hematology & Oncology, and president of medical staff at Sentara Careplex Hospital, who discussed use of 18F-rhPSMA-7.3 for PET/CT imaging and how use of the agent led to a more frequent baseline post-scan disease upstaging in men with recurrent prostate cancer compared with conventional imaging.

Results of the phase 3 SPOTLIGHT trial (NCT04186845) showed that 18F-rhPSMA-7.3 resulted in a 45% to 47% correct detection rate, defined as the rate at which patients have at least 1 true positive PET finding in comparison with the Standard of Truth histopathology or confirmatory conventional imaging.

Transcript:

It showed that we are able to upstage patients and find diseases that were missed. [Negative findings on conventional imaging give] a false sense of reassurance to patients that they didn’t have a recurrence of the disease. The increase in the upstaging of patients was dramatic. Compared with other PET imaging, this wasn’t a comparator [trial, but rather] an exploratory trial. There are other agents out there, but these are very encouraging data. I had many patients in this trial, and I was very impressed by the data that we saw, [especially] in my own patients.

Reference

Fleming MT. Impact of 18F-rhPSMA-7.3 PET on upstaging of patients with prostate cancer recurrence: results from the prospective, phase 3, multicenter, SPOTLIGHT study. Presented at: 2022 AUA Annual Meeting; May 13-16, 2022; New Orleans, LA. Abstract PLLBA-02.